Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Interest & Investment Income (2018 - 2026)

10x Genomics' Interest & Investment Income history spans 8 years, with the latest figure at $6.9 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income rose 52.88% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.0 million, a 5.91% increase, with the full-year FY2025 number at $20.0 million, up 5.91% from a year prior.
  • Interest & Investment Income hit $6.9 million in Q4 2025 for 10x Genomics, up from $5.2 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for TXG hit a ceiling of $6.9 million in Q4 2025 and a floor of $49000.0 in Q3 2021.
  • Historically, Interest & Investment Income has averaged $3.1 million across 5 years, with a median of $4.0 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: tumbled 96.21% in 2021 and later soared 5644.9% in 2022.
  • Tracing TXG's Interest & Investment Income over 5 years: stood at $49000.0 in 2021, then soared by 5644.9% to $2.8 million in 2022, then skyrocketed by 63.98% to $4.6 million in 2023, then dropped by 2.34% to $4.5 million in 2024, then surged by 52.88% to $6.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for TXG at $6.9 million in Q4 2025, $5.2 million in Q3 2025, and $4.3 million in Q2 2025.